Get to know our clinical trials
Clinical trial to compare Taquetamabl-DP or Taquetamabl-D vs. DPd in patients with refractory or relapsed multiple myeloma who have received at least 1 line of therapy
THE OBJECTIVE OF THE STUDY IS TO COMPARE THE EFFICACY OF TAL-DP AND TAL-D, RESPECTIVELY, WITH DPD.
Technical Summary
- RANDOMIZED PHASE III STUDY TO COMPARE TALQUETAMAB S.C. COMBINED WITH DARATUMUMAB S.C. AND POMALIDOMIDE (TAL-DP) OR TALQUETAMAB S.C. COMBINED WITH DARATUMUMUMAB S.C. (TAL-D) VS. DARATUMUMUMAB S.C. COMBINED WITH POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 LINE OF THERAPY. IMMUNOTHERAPY
- Code EudraCT: 2021-000202-22
- Protocol number: 64407564MMY3002
- Promoter: Janssen-Cilag
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.